Sirnaomics, Inc., which focuses on the application of nucleic acid interference technology (RNAi) for new drug creation, has completed a series D round of financing of US$105 million (about RMB730 million yuan).
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription?